![](https://porib.com/wp-content/uploads/2022/03/Cancers.jpg)
García-Sancho AM, Presa M, Pardo C, Martín-Escudero V, Oyagüez I, Ortiz-Maldonado V
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain
Cancers 2024, 16, 2301
![](https://porib.com/wp-content/uploads/2021/07/gastroenterologia_y_hepatologia.jpg)
Esteban R, Domínguez-Hernández R, Cantero H, Casado MA
Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years
Gastroenterologia y Hepatología. Doi 10.1016/j.gastrohep.2024.502199
Bustamante-Balén M, Merino Rodríguez B, Barranco Priego L, Monje J, Álvarez M, de Pedro S, Oyagüez I, Van Lent N, Mareque M
Artificial intelligence-aided colonoscopy for adenoma detection and characterization. A cost-effectiveness analysis in the Spanish setting
Congreso European Society of Gastrointestinal Endoscopy (ESGE) Days. Berlín. 25-27 abr 2024
Canut MI, García-Feijoo J, Manuel Larrosa-Poves JM, López-López F, Pazos-López M, Espinoza-Cámac N, Oyagüez I, Valor C, Del Río T, Rodríguez M
Análisis coste-utilidad de la emulsión catiónica de latanoprost frente a latanoprost en el tratamiento de pacientes con glaucoma en España
18º Congreso de la Sociedad Española de Glaucoma. Sevilla.07-09 mar 2024
![](https://porib.com/wp-content/uploads/2024/01/Liver-International.jpg)
Buti M, Domínguez-Hernández R, Palom A, Esteban R, Casado MÁ
Impact of hepatitis D reflex testing on the future disease burden: A modelling analysis
Liver International. 2023;43:2611–2614
![](https://porib.com/wp-content/uploads/2023/12/JHEP-Reports.jpg)
Llaneras J, Ruiz-Cobo JC, Rando-Segura A, Barreira-Díaz A, Domínguez-Hernández R, Rodríguez-Frías F, Campins M, Colom J, Casado MA, Blanco-Grau A, Bañares J, Monforte A, Falcó A, Ruíz L, Meza B, Pumarola T, Riveiro-Barciela M, Esteban R, Buti M
Integrating viral hepatitis management into the emergency department: A further step towards viral hepatitis elimination
JHEP Reports 2024 vol. 6 j 100932
Martín A, Presa M, Tejado N, Pardo C, Martín-Escudero V, Oyagüez I, Ortiz-Maldonado V
Eficiencia de axicabtagén ciloleucel en el tratamiento en segunda línea del linfoma B difuso de células grandes en España
LXV Congreso Nacional de la SEHH, XXXIX Congreso Nacional de la SETH y III Congreso Iberoamericano de Hematología. Sevilla. 26-28 oct 2023
Ortiz-Maldonado V, Presa M, Tejado N, Pardo C, Martín-Escudero V, Oyagüez I, Martín A
Axicabtagene Ciloleucel As Second-Line Treatment For Relapsed/ Refractory Large B-Cell Lymphoma In Spain: A Cost-Effectiveness Analysis Refractory Large B-Cell Lymphoma In Spain: A Cost-Effectiveness Analysis
26th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 12-15 nov 2023
![](https://porib.com/wp-content/uploads/2021/07/clinicoeconomics_and_outcomes_research.jpg)
Presa M, Vicente D, Calles A, Salinas-Ortega L, Naik J, García LF, Soto J